BONESUPPORT’s CERAMENT®G used in first U.S. patient cases

2022-10-24 14:00:00

BONESUPPORT, an emerging leader in orthobiologics for the management of bone injuries, today announces that the company’s antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the US. The patients treated had bone infection (osteomyelitis) caused by fractures induced by trauma.

“CERAMENT G is truly changing the way we can treat osteomyelitis by more directly and effectively addressing the site of the infection in a single stage, patient friendly surgical approach. CERAMENT G has been widely used with great success in other parts of the world and I’m pleased to integrate it in my clinical practice,” said Janet D. Conway, MD, FAAOS, board-certified orthopedic surgeon and Head of Bone and Joint Infection at Sinai Hospital of Baltimore, who carried out the first surgeries using CERAMENT G in the US.

BONESUPPORT received authorization for CERAMENT G in the management of osteomyelitis from the US Food and Drug Administration (FDA) earlier this year. The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3–5.5 percent versus 13.3 percent for the current US standard of care, PMMA-beads. CERAMENT G is the first and only FDA authorized combination antibiotic-eluting bone graft.

MFN